An evaluation of the safety and efficacy of turoctocog alfa for hemophilia A

References

• Santagostino E, Lentz SR, Misgav M, et al. Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials. Haemophilia. 2015;21(1):34–40.
   PubMed Web of Science ®Google Scholar
• Kulkarni R, Soucie JM. Pediatric hemophilia: a review. Semin Thromb Hemost. 2011;37(7):737–744.
   PubMed Web of Science ®Google Scholar
• Franchini M, Mannucci PM. Hemophilia A in the third millennium. Blood Rev. 2013;27(4):179–184.
   PubMed Web of Science ®Google Scholar
• Roosendaal G, Lafeber FP. Blood-induced joint damage in hemophilia. Semin Thromb Hemost. 2003;29(1):37–42.
   PubMed Web of Science ®Google Scholar
• Berntorp E, Astermark J, Björkman S, et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia. 2003;9(S1):1–4.
   PubMedGoogle Scholar
• Coppola A, Tagliaferri A, Di Capua M, et al. Prophylaxis in children with hemophilia: evidence-based achievements, old and new challenges. Semin Thromb Hemost. 2012;38(1):79–94.
   PubMed Web of Science ®Google Scholar
• Baunsgaard D, Nielsen AD, Nielsen PF, et al. A comparative analysis of heterogeneity in commercially available recombinant factor VIII products. Haemophilia. 2018;24(6):880–887.
   PubMed Web of Science ®Google Scholar
• Kevane B, O’Connell N. The current and future role of plasma-derived clotting factor concentrate in the treatment of haemophilia A. Transfus Apher Sci. 2018;57(4):502–506.
   PubMed Web of Science ®Google Scholar
• Iorio A, Fischer K, Makris M. Large scale studies assessing anti-factor VIII antibody development in previously untreated haemophilia A: what has been learned, what to believe and how to learn more. Br J Hematol. 2017;178(1):20–31.
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Mannucci PM, Garagiola I, et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med. 2016;374(21):2054–2064.
   PubMed Web of Science ®Google Scholar
• Astermark J, Donfield SM, Gomperts ED, et al. The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) combined cohort. Blood. 2013;121(8):1446–1454.
   PubMed Web of Science ®Google Scholar
• Martinowitz U, Bjerre J, Brand B, et al. Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®)–an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A. Haemophilia. 2011;17(6):854–859.
   PubMed Web of Science ®Google Scholar
• Burke RL, Pachl C, Quiroga M, et al. The functional domains of coagulation factor VIII:C. J Biol Chem. 1986;261(27):12574–12578.
   PubMed Web of Science ®Google Scholar
• Pittman DD, Alderman EM, Tomkinson KN, et al. Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII. Blood. 1993;81(11):2925–2935.
   PubMed Web of Science ®Google Scholar
• Bartholdy C, Reedtz-Runge SL, Wang J, et al. In silico and in vitro immunogenicity assessment of B-domain-modified recombinant factor VIII molecules. Haemophilia. 2018;24(5):e354–e62.
   PubMed Web of Science ®Google Scholar
• Thim L, Vandahl B, Karlsson J, et al. Purification and characterization of a new recombinant factor VIII (N8). Haemophilia. 2010;16(2):349–359.
   PubMed Web of Science ®Google Scholar
• Nielsen PF, Bak S, Vandahl B. Characterization of tyrosine sulphation in rFVIII (turoctocog alfa) expressed in CHO and HEK-293 cells. Haemophilia. 2012;18(5):e397–8.
   PubMed Web of Science ®Google Scholar
• Ezban M, Vad K, Kjalke M. Turoctocog alfa (NovoEight®)–from design to clinical proof of concept. Eur J Haematol. 2014;93(5):369–376.
   PubMed Web of Science ®Google Scholar
• Santagostino E. A new recombinant factor VIII: from genetics to clinical use. Drug Des Devel Ther. 2014;8:2507–2515.
   PubMed Web of Science ®Google Scholar
• Medzihradszky KF. Characterization of protein N-glycosylation. Methods Enzymol. 2005;405:116–138.
   PubMed Web of Science ®Google Scholar
• Kannicht C, Ramström M, Kohla G, et al. Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII. Thromb Res. 2013;131(1):78–88.
   PubMed Web of Science ®Google Scholar
• Azzi A, De Santis R, Morfini M, et al. TT virus contaminates first-generation recombinant factor VIII concentrates. Blood. 2001;98(8):2571–2573.
   PubMed Web of Science ®Google Scholar
• Grillberger L, Kreil TR, Nasr S, et al. Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells. Biotechnol J. 2009;4(2):186–201.
   PubMedGoogle Scholar
• Morfini M. Innovative approach for improved rFVIII concentrate. Eur J Haematol. 2014;93(5):361–368.
   PubMed Web of Science ®Google Scholar
• Ellgaard TW, Bindslev L, Kamstrup S. Evaluation of the virus clearance capacity and robustness of the manufacturing process for the recombinant factor VIII protein, turoctocog alfa. Protein Exp Purif. 2017;129:94–100.
   PubMed Web of Science ®Google Scholar
• Ahmadian H, Hansen EB, Faber JH, et al. Molecular design and downstream processing of turoctocog alfa (NovoEight), a B-domain truncated factor VIII molecule. Blood Coagul Fibrinolysis. 2016;27(5):568–575.
   PubMed Web of Science ®Google Scholar
• Elm T, Karpf DM, Øvlisen K, et al. Pharmacokinetics and pharmacodynamics of a new recombinant FVIII (N8) in haemophilia A mice. Haemophilia. 2012;18(1):139–145.
   PubMed Web of Science ®Google Scholar
• Karpf DM, Kjalke M, Thim L, et al. Pharmacokinetics and ex vivo whole blood clot formation of a new recombinant FVIII (N8) in haemophilia A dogs. Haemophilia. 2011;17(5):e963–8.
   PubMed Web of Science ®Google Scholar
• Christiansen ML, Balling KW, Persson E, et al. Functional characteristics of N8, a new recombinant FVIII. Haemophilia. 2010;16(6):878–887.
   PubMed Web of Science ®Google Scholar
• Barrowcliffe TW, Raut S, Hubbard AR. Discrepancies in potency assessment of recombinant FVIII concentrates. Haemophilia. 1998;4(4):634–640.
   PubMed Web of Science ®Google Scholar
• Mikaelsson M, Oswaldsson U, Jankowski MA. Measurement of factor VIII activity of B-domain deleted recombinant factor VIII. Semin Hematol. 2001;38(2 Suppl 4):13–23.
   PubMed Web of Science ®Google Scholar
• Viuff D, Barrowcliffe T, Saugstrup T, et al. International comparative field study of N8 evaluating factor VIII assay performance. Haemophilia. 2011;17(4):695–702.
   PubMed Web of Science ®Google Scholar
• Jiménez-Yuste V, Lejniece S, Klamroth R, et al. The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A. J Thromb Haemost. 2015;13(3):370–379.
   PubMed Web of Science ®Google Scholar
• Gringeri A, Lundin B, von Mackensen S, et al. A randomized clinical trial of prophylaxis in children with hemophilia A (The ESPRIT study). J Thromb Haemost. 2011;9(4):700–710.
   PubMed Web of Science ®Google Scholar
• Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535–544.
   PubMed Web of Science ®Google Scholar
• Hoots WK, Nugent DJ. Evidence for the benefits of prophylaxis in the management of hemophilia A. Thromb Haemost. 2006;96(4):433–440.
   PubMed Web of Science ®Google Scholar
• Gouw SC, van der Bom JG, Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood. 2007;109(11):4648–4654.
   PubMed Web of Science ®Google Scholar
• Royal S, Schramm W, Berntorp E, et al. Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients. Haemophilia. 2002;8(1):44–50.
   PubMed Web of Science ®Google Scholar
• Lentz SR, Misgav M, Ozelo M, et al. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy. Haemophilia. 2013;19(5):691–697.
   PubMed Web of Science ®Google Scholar
• Valentino LA, Mamonov V, Hellmann A, et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost. 2012;10(3):359–367.
   PubMed Web of Science ®Google Scholar
• Lusher JM, Roth DA. The safety and efficacy of B-domain deleted recombinant factor VIII concentrates in patients with severe haemophilia A: an update. Haemophilia. 2005;11(3):292–293.
   PubMed Web of Science ®Google Scholar
• Lusher JM, Lee CA, Kessler CM, et al. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia. 2003;9(1):38–49.
   PubMed Web of Science ®Google Scholar
• Kulkarni R, Karim FA, Glamocanin S, et al. Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics. Haemophilia. 2013;19(5):698–705.
   PubMed Web of Science ®Google Scholar
• Blanchette VS, Shapiro AD, Liesner RJ, et al. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost. 2008;6(8):1319–1326.
   PubMed Web of Science ®Google Scholar
• Lentz SR, Janic D, Kavakli K, et al. Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: final results from the guardian 2 extension trial. Haemophilia. 2018;24(6):e391–4.
   PubMed Web of Science ®Google Scholar
• Pocoski J, Li N, Ayyagari R, et al. Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A. J Blood Med. 2016;7:129–137.
   PubMed Web of Science ®Google Scholar
• Lentz SR, Cerqueira M, Janic D, et al. Interim results from a large multinational extension trial (Guardian(™) 2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A. Haemophilia. 2016;22(5):e445–9.
   PubMed Web of Science ®Google Scholar
• Ozelo M, Misgav M, Abdul Karim F, et al. Long-term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight(®)) in previously treated patients with severe haemophilia A: interim results of the guardian(™) 2 extension trial. Haemophilia. 2015;21(5):e436–9.
   PubMed Web of Science ®Google Scholar
• Escobar MA, Brewer A, Caviglia H, et al. Recommendations on multidisciplinary management of elective surgery in people with haemophilia. Haemophilia. 2018 Sep;24(5):693–702.
   PubMed Web of Science ®Google Scholar
• Takeyama M, Nogami K, Kobayashi R, et al. Continuous infusions of B domain-truncated recombinant factor VIII, turoctocog alfa, for orthopedic surgery in severe hemophilia A: first case report. Int J Hematol. 2018;108(2):199–202.
   PubMed Web of Science ®Google Scholar
• Holme PA, Tjønnfjord GE, Batorova A. Continuous infusion of coagulation factor concentrates during intensive treatment. Haemophilia. 2018;24(1):24–32.
   PubMed Web of Science ®Google Scholar
• Rosendaal FR, Smit C, Varekamp I, et al. Modern haemophilia treatment: medical improvements and quality of life. J Intern Med. 1990;228(6):633–640.
   PubMed Web of Science ®Google Scholar
• Khair K, Lawrence K, Butler R, et al. Assessment of treatment practice patterns for severe hemophilia A: a global nurse perspective. Acta Haematol. 2008;119(2):115–123.
   PubMed Web of Science ®Google Scholar
• Santagostino E, Lentz SR, Busk AK, et al. Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa. Haemophilia. 2014;20(4):527–534.
   PubMed Web of Science ®Google Scholar
• Fischer K, van der Bom JG, van den Berg HM. Health-related quality of life as outcome parameter in haemophilia treatment. Haemophilia. 2003;9(Suppl 1):75–81; discussion 82.
   PubMedGoogle Scholar
• Ozelo M, Chowdary P, Regnault A, et al. Impact of severe haemophilia A on patients’ health status: results from the guardian(™) 1 clinical trial of turoctocog alfa (NovoEight(®)). Haemophilia. 2015;21(4):451–457.
   PubMed Web of Science ®Google Scholar
• The EuroQol group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208.
   PubMed Web of Science ®Google Scholar
• Taki M, Fukutake K, Matsushita T, et al. Inhibitor development, safety, and efficacy of Advate® in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan. Int J Hematol. 2019;109(1):70–78.
   PubMed Web of Science ®Google Scholar
• Ozelo M, Wu R, Belhani M, et al. Guardian TM 4: safety and efficacy of turoctocog alfa in prevention and treatment of bleeds in previously untreated patients with hemophilia A. Haemophilia. 2019;25(S1):101–102.
   PubMedGoogle Scholar
• Collins PW, Palmer BP, Chalmers EA, et al. Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000–2011. Blood. 2014;124(23):3389–3397.
   PubMed Web of Science ®Google Scholar
• Gouw SC, van der Bom JG, Ljung R, et al. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med. 2013;368(3):231–239.
   PubMed Web of Science ®Google Scholar
• Calvez T, Chambost H, Claeyssens-Donadel S, et al. Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A. Blood. 2014;124(23):3398–3408.
   PubMed Web of Science ®Google Scholar
• Volkers P, Hanschmann KM, Calvez T, et al. Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: combined analysis of three studies. Haemophilia. 2019;25(3):398–407.
   PubMed Web of Science ®Google Scholar
• Gouw SC, van den Berg HM, Oldenburg J, et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood. 2012;119(12):2922–2934.
   PubMed Web of Science ®Google Scholar
• Lai J, Hough C, Tarrant J, et al. Biological considerations of plasma-derived and recombinant factor VIII immunogenicity. Blood. 2017;129(24):3147–3154.
   PubMed Web of Science ®Google Scholar
• Osooli M, Berntorp E. Inhibitors in haemophilia: what have we learned from registries? A systematic review. J Intern Med. 2015;277(1):1–15.
   PubMed Web of Science ®Google Scholar
• Pavlova A, Delev D, Lacroix-Desmazes S, et al. Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A. J Thromb Haemost. 2009;7(12):2006–2015.
   PubMed Web of Science ®Google Scholar
• Astermark J, Wang X, Oldenburg J, et al. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost. 2007;5(2):263–265.
   PubMed Web of Science ®Google Scholar
• Platokouki H, Fischer K, Gouw SC, et al. Vaccinations are not associated with inhibitor development in boys with severe haemophilia A. Haemophilia. 2018;24(2):283–290.
   PubMed Web of Science ®Google Scholar
• Feistritzer C, Wildner SM, Würtinger P, et al. Successful immune tolerance induction using turoctocog alfa in an adult haemophilia A patient. Blood Coagul Fibrinolysis. 2017;28(2):181–184.
   PubMed Web of Science ®Google Scholar
• Zanon E, Milan M, Pasca S. Immune tolerance induction rescue with turoctocog-alfa in a poor risk haemophilia A inhibitor young child: the history of a success. Blood Coagul Fibrinolysis. 2018;29(5):465–468.
   PubMed Web of Science ®Google Scholar
• Zupančić-Šalek S, Vodanović M, Pulanić D, et al. A case report of acute inferior myocardial infarction in a patient with severe hemophilia A after recombinant factor VIII infusion. Medicine (Baltimore). 2017;96(52):e9075.
   PubMed Web of Science ®Google Scholar
• Takedani H, Hirose J. Turoctocog alfa: an evidence-based review of its potential in the treatment of hemophilia A. Drug Des Devel Ther. 2015;9:1767–1772.
   PubMed Web of Science ®Google Scholar
• Vakil NH, Fujinami N, Martin-Stone S. Turoctocog alfa for the treatment of hemophilia A. Pharmacotherapy. 2014;34(10):1091–1101.
   PubMed Web of Science ®Google Scholar
• Toole JJ, Pittman DD, Orr EC, et al. A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity. Proc Natl Acad Sci U S A. 1986;83(16):5939–5942.
   PubMed Web of Science ®Google Scholar
• Giangrande P, Andreeva T, Chowdary P, et al. Clinical evaluation of glycoPEGylated recombinant FVIII: efficacy and safety in severe haemophilia A. Thromb Haemost. 2017;117(2):252–261.
   PubMed Web of Science ®Google Scholar